BRAF and melanoma: According to the latest ASCO guidelines, ipilimumab in association with nivolumab, followed by nivolumab monotherapy, is recommended for unresectable/metastatic cutaneous melanoma, alternatively to anti-PD1 or BRAF inhibitors and MEK inhibitors (the latter in the case of BRAF V600 mutated melanoma).